drugset / Trial / NCT02587364

Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers

NCT02587364

Phase 1 Completed 50 enrolled NeuroBo Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate the multiple-dose pharmacokinetic characteristics and pharmacologic activity of gemcabene.

Timeline

Start
1999-04
Primary completion
1999-09
Completion
1999-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcabene Small molecule 50 mg
Subject Gemcabene Small molecule 150 mg
Subject Gemcabene Small molecule 450 mg
Subject Gemcabene Small molecule 600 mg
Subject Gemcabene Small molecule 750 mg
Subject Gemcabene Small molecule 900 mg

Indications